EI
SYRE icon

EAM Investors’s Spyre Therapeutics SYRE Stock Holding History

EAM Investors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,938
Closed -$422K – 327
2024
Q2 		$422K Hold
17,938
– – 0.07% 238
2024
Q1 		$680K Buy
+17,938
New +$520K 0.11% 215
2018
Q3 		– Sell
-2,269
Closed -$600K – 366
2018
Q2 		$600K Hold
2,269
– – 0.09% 273
2018
Q1 		$563K Buy
+2,269
New +$410K 0.09% 265

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's SYRE Position: Q3 2024 in Review

EAM Investors sold out of Spyre Therapeutics (SYRE) in Q3 2024, closing a stake of 17,938 shares — an estimated $422K sold.

EAM Investors first reported a position in SYRE in Q1 2018 and held it in 4 quarters. The position peaked at $680K in Q1 2024. 119 funds tracked by Wall St. Rank hold SYRE as of Q3 2024.

  • EAM Investors reported no remaining Spyre Therapeutics position as of Q3 2024 after selling out during the quarter.
  • EAM Investors sold 17,938 Spyre Therapeutics shares in Q3 2024, an estimated $422K.
  • EAM Investors first reported a position in Spyre Therapeutics in Q1 2018 and held it in 4 quarters.
  • EAM Investors's Spyre Therapeutics position peaked at $680K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2024.

Based on EAM Investors's 13F filing for Q3 2024, filed 13 Nov 2024.